Alkermes to Present Sustained Efficacy Data for Alixorexton in Narcolepsy Type 1
Phase 2 Vibrance-1 study extension shows sustained improvements in patient-reported disease severity, cognitive functioning, and fatigue.
Tag: Phase 2
All
Latest
All
Latest
First Orexin Agonist in Phase 3 Trials for Narcolepsy
A phase 3 readout is anticipated later this year.
All
LatestSorry, No Posts Found
Can Inspiratory Muscle Training Lower Blood Pressure in Sleep Apnea Patients? Clinical Trial Aims to Find Out
A five-year, $3.4 million grant builds on research that showed a respiratory workout entailing 30 breaths a day can lower blood pressure.
Read More
First Patient Dosed in Sleep Apnea Pill Second Phase 2 Clinical Trial
A total of 30 participants will be enrolled. Each participant will receive two different dose levels of AD109, and placebo, at bedtime.
Read MoreFirst Patient Dosed in Sleep Apnea Pill Phase 2 Clinical Trial
Apnimed’s AD109 is dosed once-daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity.
Read MoreAxsome Therapeutics’ AXS-12 Achieves Primary Endpoint in Phase 2 Trial in Narcolepsy
Axsome Therapeutics Inc announced that AXS-12 (reboxetine) met the prespecified primary endpoint and significantly reduced the number of cataplexy attacks as compared to placebo in patients with narcolepsy in the CONCERT Phase 2...
Read More